Nuvation Bio Inc expected to post a loss of 11 cents a share - Earnings Preview

Nuvation Bio

24/02/2023 15:13

* Nuvation Bio Inc  NUVB.N   NUVB.K  is expected to show no
change
in quarterly revenue when it reports  results on February 27
(estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Nuvation Bio Inc is
for a
loss of 11 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Nuvation
Bio Inc
is $4.5​, above​ its last closing price of $2.07. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.14       -0.14      -0.12     Beat    14.3
 Jun. 30 2022  -0.13       -0.13      -0.16     Missed  -20.4
 Mar. 31 2022  -0.14       -0.14      -0.10     Beat    30.6​
 Dec. 31 2021  -0.12       -0.12      -0.12     Met     -1.4
 ​​Sep.        -0.11       -0.11      -0.11     Met     -3.8
 30 2021                                                
 Jun. 30 2021  -0.10       -0.10      -0.09     Beat    8.2​
 Mar. 31 2021  -0.07       -0.07      -0.12     Missed  -71.4
 Dec. 31 2020              -0.05                        
 This summary was machine generated February 24 at 15:13 GMT. 
All figures in US dollars  unless otherwise stated